Human Genome Epidemiology Literature Finder
Records 1 - 12 (of 12 Records) |
Query Trace: Epilepsy and CYP3A5[original query] |
---|
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013 Jan 14 (1): 1. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK |
CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. BioMed research international 2013 2013 526837. Emich-Widera Ewa, Likus Wirginia, Kazek Beata, Niemiec Pawe?, Balcerzyk Anna, Siero? Aleksander L, Zak Iwo |
Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy. Pharmacogenomics 2014 15 (15): 1867-79. Zhu Xu, Yun Wenting, Sun Xiaofu, Qiu Feng, Zhao Limei, Guo Yingj |
Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy research 2015 Sep 117 52-57. Wang Ping, Yin Tao, Ma Hong-Ying, Liu Dan-Qi, Sheng Yang-Hao, Wang Can, Zhou Bo-Ti |
The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children. Seizure 2016 Jul 41 75-80. Abo El Fotoh Wafaa Moustafa M, Abd El Naby Sameh Abd Allah, Habib Mona Salah El-Din, ALrefai Abeer Ahmed, Kasemy Zeinab |
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics 2016 Oct . Fricke-Galindo Ingrid, Ortega-Vázquez Alberto, Monroy-Jaramillo Nancy, Dorado Pedro, Jung-Cook Helgi, Peñas-Lledó Eva, LLerena Adrián, López-López Maris |
A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information. PloS one 2017 12 (1): e0169214. Silva-Alves Mariana S, Secolin Rodrigo, Carvalho Benilton S, Yasuda Clarissa L, Bilevicius Elizabeth, Alvim Marina K M, Santos Renato O, Maurer-Morelli Claudia V, Cendes Fernando, Lopes-Cendes Isc |
Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case-control study. Pharmacogenomics and personalized medicine 2019 12 225-233. Al-Eitan Laith N, Al-Dalalah Islam M, Mustafa Mohamed M, Alghamdi Mansour A, Elshammari Afrah K, Khreisat Wael H, Al-Quasmi Mohammed N, Aljamal Hanan |
CYP3A5 genetic variants and their associations with carbamazepine and valproic acid response in Malaysian epileptic patients. International journal of clinical pharmacology and therapeutics 2020 10 59 (1): 8-16. Miyata-Nozaka Yuka, Tan Hui Jan, Wong Sau Wei, Raymond Azman Ali, Omar Haslyna, Zain Shamsul Mo |
Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis. Epilepsy research 2021 Mar 173 106615. Zhao Gui-Xin, Zhang Zheng, Cai Wen-Ke, Shen Ming-Li, Wang Ping, He Gong-H |
Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital. Pharmacogenomics 2021 10 22 (15): 983-996. Fricke-Galindo Ingrid, Jung-Cook Helgi, Martínez-Juárez Iris E, Monroy-Jaramillo Nancy, Ortega-Vázquez Alberto, Rojas-Tomé Irma S, Dorado Pedro, Peñas-Lledó Eva, Llerena Adrián, López-López Maris |
ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study. Seizure 2022 3 97 58-62. Mousavi Seyedeh Farnaz, Hasanpour Kazem, Nazarzadeh Milad, Adli Abolfazl, Bazghandi Malihe Sadat, Asadi Alireza, Rad Abolfazl, Gholami Om |
- Page last reviewed:Feb 1, 2024
- Page last updated:Mar 25, 2024
- Content source: